|
Vaccine Detail
B. anthracis DNA Vaccine expressing PA |
Vaccine Information |
- Vaccine Name: B. anthracis DNA Vaccine expressing PA
- Target Pathogen: Bacillus anthracis
- Target Disease: Anthrax
- Vaccine Ontology ID: VO_0004543
- Type: DNA vaccine
- Status: Research
- pagA
gene engineering:
- Type: DNA vaccine construction
- Description:
- Detailed Gene Information: Click Here.
- DNA vaccine plasmid:
- DNA vaccine plasmid name:
- DNA vaccine plasmid VO ID: VO_0000024
- Immunization Route: Intramuscular injection (i.m.)
|
Host Response |
Macaque Response
- Vaccination Protocol: Four groups of five animals each were assigned to the vaccine recipient groups; two animals were held as unimmunized controls. All experimental groups received intramuscular injection of vaccine at days 0 and 56 in the quadriceps. One group of rhesus macaques was immunized with 0.5 mL of Biothrax, the approved human dose. Another group was injected intramuscularly with 1.5 mg of pIMS-120. Two groups of animals were immunized with either 0.3 or 1.5 mg of pIMS-120 using an EP device referred to as the TriGrid Delivery System (TDS) (Livingston et al., 2010).
- Immune Response: EP delivery effectively induced anti-PA neutralizing antibody responses in 100% of subjects at both dose levels (Livingston et al., 2010).
- Challenge Protocol: One year after the first immunization, the rhesus macaques were exposed to a targeted dose of 100 LD50 spores of Ames isolate of B. anthracis (Livingston et al., 2010).
- Efficacy: For the animals administered the pIMS-120 candidate by EP delivery, 40% (2/5) of the animals administered the 0.3 mg DNA dose and 80% (4/5) administered the 1.5 mg DNA dose survived the challenge (Livingston et al., 2010).
|
References |
Livingston et al., 2010: Livingston BD, Little SF, Luxembourg A, Ellefsen B, Hannaman D. Comparative performance of a licensed anthrax vaccine versus electroporation based delivery of a PA encoding DNA vaccine in rhesus macaques. Vaccine. 2010; 28(4); 1056-1061. [PubMed: 19896452].
|
|